本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Opko Health

1.41
-0.0500-3.42%
盤後1.470.0600+4.26%19:51 EDT
成交量:329.96萬
成交額:468.89萬
市值:9.47億
市盈率:-18.39
高:1.46
開:1.44
低:1.40
收:1.46
資料載入中...

公司資料

公司名字:
Opko Health
交易所:
NASDAQ
成立時間:
2007
員工人數:
2997
公司地址:
4400 Biscayne Boulevard,Miami,Florida,United States
郵編:
33137
傳真:
- -
簡介:
OPKO Health, Inc.最初於1991年10月在特拉華州註冊成立。該公司是一家多元化的醫療保健公司,尋求在大型且快速增長的醫療市場中建立行業領先地位。該公司的製藥業務包括美國食品藥品監督管理局(Food and Drug Administration)批準的用於治療患有3或4期慢性腎病和維生素D不足的成人繼發性甲狀旁腺功能亢進的Rayaldee,以及每周一次的人生長激素注射液Somatrogon,該公司已與輝瑞公司就Somatrogon的進一步開發和商業化進行合作。

董事

名稱
職位
Elias A. Zerhouni
Vice Chairman of the Board and President
Jane H. Hsiao
Vice Chairman of the Board and Chief Technical Officer
Phillip Frost
Chairman of the Board and Chief Executive Officer
Gary J. Nabel
Director and Chief Innovation Officer
Steven D. Rubin
Director and Executive Vice President-Administration
Alexis Borisy
Director
Alice Lin Tsing Yu
Director
John A. Paganelli
Director
Prem A. Lachman
Director
Richard C. Pfenniger, Jr.
Director
Richard M. Krasno
Director
Roger J. Medel
Director

股東

名稱
職位
Phillip Frost
Chairman of the Board and Chief Executive Officer
Adam Logal
Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer
Elias A. Zerhouni
Vice Chairman of the Board and President
Gary J. Nabel
Director and Chief Innovation Officer
Jane H. Hsiao
Vice Chairman of the Board and Chief Technical Officer
Steven D. Rubin
Director and Executive Vice President-Administration